LUNDBECK, LLC

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining epilepsy drug bexicaserin. The deal aims to develop a neuro-rare disease franchise, focusing on bexicaserin's potential to treat Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin has shown significant seizure reduction in Phase 1b/2a studies and received breakthrough therapy designation from the FDA. Lundbeck plans to launch the drug in 2028 with peak sales potential of up to $2 billion.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn, enhancing its neuro-rare conditions portfolio with bexicaserin, currently in Phase III clinical trials for developmental and epileptic encephalopathies.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, an epilepsy drug in late-stage testing for developmental and epileptic encephalopathies (DEEs), with potential peak sales of $1.5-2.0 billion by 2028.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining access to its novel epilepsy drug, bexicaserin, which targets 5-HT2C receptors and has FDA breakthrough therapy designation. The deal, Lundbeck's largest, aims to address unmet needs in rare and severe epilepsies, with bexicaserin expected to launch by 2028 with potential sales of $1.5-$2 billion.

Lundbeck acquires Longboard Pharmaceuticals for DKK 17bn (USD 2.5bn), with CEO Charl van Zyl deeming the price reasonable.

Lundbeck enhances neuroscience drug pipeline.

Lundbeck to acquire Longboard Pharmaceuticals, gaining access to bexicaserin, a promising 5-HT2C receptor agonist for treating rare developmental epileptic encephalopathies. The deal includes a tender offer of $2.6 million per share and integration costs of $80 million.

Lundbeck agreed to acquire Longboard Pharmaceuticals for US$2.6 billion, offering US$60 per share in cash to boost its drug pipeline for serious brain diseases. Longboard's main drug, bexicaserin, shows potential for treating rare epilepsies. The deal is expected to close in Q4, funded by existing cash and bank financing.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6B, enhancing its neuroscience pipeline with bexicaserin, a late-stage treatment for Developmental and Epileptic Encephalopathies (DEEs). The acquisition aligns with Lundbeck’s Focused Innovator strategy and aims to address high unmet medical needs in neuro-rare conditions. Bexicaserin, a 5-HT2C receptor superagonist, has shown promising anti-seizure effects and is in a global phase III trial for Dravet syndrome.

K.W. is a member of the ACTIVE Workgroup supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. J.L.M., B.P.L., and M.C.M. are consultants for GlaxoSmithKline, Novo Nordisk, HepaTX, and Prodigy. M.C.M. also serves on the Board of Amygdala Neuroscience and receives research support from Durect. Other authors declare no competing interests.